ENDRA Life Sciences Inc.(NDRA)Earnings, Financials & Key RatiosENDRA Life Sciences Inc. (NDRA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current ratio of 0.64 and the depletion of cash to $356,500 indicate a high probability of further dilutive financing or potential going concern risks.
ENDRA Life Sciences Inc. (NDRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
ENDRA Life Sciences Inc. (NDRA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $1.09vs $1.23+11.4% | — |
| Q2 2026 | May 15, 2026 | $1.09vs $1.23+11.4% | — |
| Q2 2026 | Mar 31, 2026 | $3.26vs $1.23-165.0% | —vs $100,000 |
| Q4 2025 | Nov 14, 2025 | $1.75vs $1.95+10.3% | — |
Recent stock market news and headlines for ENDRA Life Sciences Inc. (NDRA)
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the proposed transaction, ENDRA shareholders are expected to own approximately 3% of the combined company.Halper Sadeh encourages ENDRA shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or zhalp.
ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," âASPIâ or the "Company"), an advanced materials company focused on developing technologies and processes
DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that ASP Isotopes' wholly-owned su.
Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen's Virginia Gas Project Listing expected to provide investors with direct exposure to one of the few publicly traded helium development assets globally, at a time of tightening supply Concurrent private placement expected to generate approximately $50 million in gross proceeds to support project development DALLAS and ANN ARBOR, Mich.
Key metrics vs top competitors for ENDRA Life Sciences Inc. (NDRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.95 | $3.73M | -0.55 | — | — | -291.56% | — | |
| $5.33 | $222.76M | -3.21 | 56.89% | -214.16% | -130% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $17.48 | $524.22M | -19.42 | 17.78% | -71.57% | -140.96% | — |
ENDRA Life Sciences Inc. (NDRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENDRA Life Sciences Inc. (NDRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 28, 2026·SEC
Apr 21, 2026·SEC
Mar 31, 2026·SEC
Get notified when NDRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENDRA Life Sciences Inc. (NDRA) stock FAQ — growth, dividends, profitability & financials explained
ENDRA Life Sciences Inc. (NDRA) reported a net loss of $7.3M for fiscal year 2025.
ENDRA Life Sciences Inc. (NDRA) has a return on equity (ROE) of -291.6%. Negative ROE indicates the company is unprofitable.
ENDRA Life Sciences Inc. (NDRA) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.
